Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2021-03-16 Audit Report / Informat…
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Access Bio. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and key financial metrics for the fiscal year. While it is an announcement of the audit report, it provides the core financial data and audit results directly within the filing, which is standard for Korean regulatory filings (DART) regarding audit report submissions. Given the specific content and the regulatory nature of the disclosure, it is classified as an Audit Report/Information document. FY 2020
2021-03-16 Korean
사업보고서 (2020.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 19th fiscal year (2020) of Access Bio, Inc. It contains comprehensive financial statements, management discussion and analysis, governance information, and audit details. This is the standard Korean regulatory filing equivalent to a 10-K, which provides a full annual overview of the company's performance and financial status. FY 2020
2021-03-16 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Access Bio, which includes the agenda, details on director appointments, remuneration limits, and financial statements for the upcoming meeting. It also contains a 'Correction Report' (정정신고) regarding the remuneration figures. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes, fitting the definition of a Proxy Solicitation & Information Statement.
2021-03-16 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Access Bio, Inc. It includes the agenda for the meeting, details on director re-elections, financial statement approval, and proxy voting instructions (의결권행사신청서). This document is designed to provide shareholders with the necessary information to vote at the upcoming Annual General Meeting. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2021-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Access Bio, Inc. It outlines the meeting date, location, agenda items (such as approval of financial statements, election of directors, and remuneration limits), and provides detailed background information for shareholders to vote on these matters. This document is a standard proxy statement/notice of meeting sent to shareholders to solicit their votes for the upcoming AGM.
2021-03-05 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory announcement regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) for COVID-19 antigen diagnostic kits. It details the contract value, the counterparty (Intrivo Diagnostics), and the contract period. In the context of Korean regulatory filings (DART), this is a standard disclosure of a major contract, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A or share issues.
2021-02-24 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.